Discovery and identification of anti-U1-A snRNP antibody in lung cancer
Tóm tắt
There are multiple reports of autoimmune response in patients with lung cancer. To investigate whether a novel autoantibody is present in patients with lung cancer and evaluate its clinical diagnostic and prognostic value, sera from 10 patients with lung cancer and 10 normal individuals were analyzed using immunofluorescence and Western blotting. It was found that one serum sample from the patients with squamous carcinoma gave a fine speckled pattern staining in nucleus and had a high titer antinuclear autoantibody which could recognize 31 kD of nuclear protein isolated from both cancer cells and normal cells. The same patient’s serum was further used to immunoprecipitate the target antigen. The protein bands were excised from the SDS-PAGE gels and were analyzed with a Qstar Pulser I Quadrupole time-flight mass spectrometer, and the 31 kD target antigen was identified as U1-AsnRNP. To test the prevalence of anti-U1-AsnRNP antibody, sera from 93 patients including 36 squmaous carcinomas (SCC), 26 adenocarcinomas (Ad), and 31 small cell carcinomas (SCLC) were screened by Western blotting. The results demonstrated that anti-U1-A snRNP antibody was present in 50% of SCC sera, 26.9% of Ad sera and 54.8% of SCLC sera. In this paper, we report for the first time that anti-U1-AsnRNP antibody could be detected in the patients with lung cancer.
Tài liệu tham khảo
Soussi, T., p53 antibodies in the sera of patients with various types of cancer: A review, Cancer Res., 2000, 60: 1777–1788.
Tomkiel, J. E., Alansari, H., Tang, N. et al., Autoimmunity to the Mr. 32000 subunit of replication protein A in breast cancer, Clin. Cancer Res., 2002, 8: 752–758.
Felix, F. M., Pamela, J., Vande, V. et al., Antinuclear antibodies as potential markers of lung cancer, Clin. Cancer Res., 1999, 5: 1393–1400.
Zeng, C., He, D., Berget, S. M. et al., Nuclear-Mitotic apparatus protein: Structural protein interface between the nucleoskeleton and RNA splicing, Proc. Natl. Acad. Sci. USA, 1994, 91: 1505–1509.
Xiao, X. Y., Liu, D. H., Tang, Y. et al., Development of proteomic patterns for detecting lung cancer, Dis. Markers, 2003, 19(1): 33–39.
Chen, P., Xie, J. Y., Liang, S. P., Identification of protein spots in sliver-stained two-dimensional gels by MALDI-TOF mass peptide map analysis, Acta Biochim. Biophys. Sin., 2000, 32: 387–391.
Adam, B. L., Qu, Y., Davis, J. W. et al., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men, Cancer Res., 2002, 62: 3609–3614.
Petricoin, III E. F., Ardekani, A. M., Hitt, B. A. et al., Use of proteomic patterns in serum to identify ovarian cancer, The Lancet, 2002, 359: 572–577.
Xiao, X. Y., Zhao, X., Liu, J. K. et al., Discovery of laryngeal carcinoma by serum proteomic pattern analysis, Sci. China, 2004, 47(3): 219–223.
Félix, F. M., Pamela, J., Vande, V. et al., Antinuclear antibodies as potential markers of lung cancer, Clin. Cancer Res., 1999, 5: 1393–1400.
Kubo, M., Ihn, H., Kuwana, M. et al., Anti-U5 snRNP antibody as a possible serological marker for scleroderma-polymyositis overlap, Rhrumatology, 2002, 41: 531–534.